Filters: keyword is & [Clear All Filters]
- 2008
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42. DOI
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84. DOI
Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex,
Br J Pharmacol, vol. 154, no. 6, pp. 1369-78. DOI
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes,
Am J Obstet Gynecol, vol. 198, no. 1, pp. 108 e1-6. DOI
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38. DOI
The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women,
Br J Clin Pharmacol, vol. 66, no. 6, pp. 866-74. DOI
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55. DOI
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat,
Pharm Res, vol. 25, no. 4, pp. 792-804. DOI
- 2007
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks,
Antimicrob Agents Chemother, vol. 51, no. 10, pp. 3720-5. DOI
Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior,
Eur J Pharm Sci, vol. 32, no. 3, pp. 200-8. DOI
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats,
J Pharmacol Exp Ther, vol. 321, no. 2, pp. 598-607. DOI
Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint,
Br J Pharmacol, vol. 151, no. 3, pp. 356-66. DOI
Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy,
Epilepsia, vol. 48, no. 7, pp. 1378-87. DOI
Application of the convection-dispersion equation to modelling oral drug absorption,
Bull Math Biol, vol. 69, no. 1, pp. 181-95. DOI
Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update,
Eur J Pharm Sci, vol. 30, no. 2, pp. 107-12. DOI
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers,
Clin Pharmacokinet, vol. 46, no. 11, pp. 965-80. DOI
- 2006
A model-based approach to treatment comparison in acute migraine,
Br J Clin Pharmacol, vol. 62, no. 5, pp. 591-600. DOI
Buprenorphine induces ceiling in respiratory depression but not in analgesia,
Br J Anaesth, vol. 96, no. 5, pp. 627-32. DOI
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients,
Eur J Clin Pharmacol, vol. 62, no. 3, pp. 185-94. DOI
Naloxone reversal of buprenorphine-induced respiratory depression,
Anesthesiology, vol. 105, no. 1, pp. 51-7. DOI
Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation,
J Pharm Sci, vol. 95, no. 7, pp. 1570-85. DOI
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery,
Anesthesiology, vol. 105, no. 6, pp. 1135-46. DOI
Prediction of headache response in migraine treatment,
Cephalalgia, vol. 26, no. 4, pp. 416-22. DOI
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21. DOI
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain,
Eur J Pharmacol, vol. 514, no. 2-3, pp. 131-40. DOI


